Suche
Beiträge, die mit Access2meds getaggt sind
Dr Matthew Rimmer is a Professor in Intellectual Property and Innovation Law at the Faculty of Business and Law, at the Queensland University of Technology (QUT). He has published widely on copyright law and information technology, patent law and biotechnology, access to medicines, plain packaging of tobacco products, intellectual property and climate change, Indigenous Intellectual Property, and intellectual property and trade. He is undertaking research on intellectual property and 3D printing; the regulation of robotics and artificial intelligence; and intellectual property and public health (particularly looking at the coronavirus COVID-19). His work is archived at QUT ePrints, SSRN Abstracts, Bepress Selected Works, and Open Science Framework.
https://www.qut.edu.au/about/our-people/academic-profiles/matthew.rimmer
https://works.bepress.com/matthew_rimmer/
https://www.linkedin.com/in/drmatthewrimmer/
https://papers.ssrn.com/sol3/cf_dev/AbsByAuth.cfm?per_id=358042
https://works.bepress.com/matthew_rimmer/
#auslaw #auspol #IP #copyright #trademark #plainpacks #patent #PBR #access2meds #tradesecrets #SDGs #climate #IndigenousIP #trade #TPP #3dprinting #robotics #innovation
Posts will also feature #books #music #film #TV #photography - some sport #AFL #football #socceroos #LFC #YNWA #basketball. There will also be the odd post about #dogs #labradors and #swimming
MSF responds to groundbreaking news that Johnson & Johnson will not enforce patents on key TB drug bedaquiline in low- and middle-income countries
MSF welcomes Johnson & Johnson's intent not to enforce its patents on key TB drug bedaquiline, paving way for affordable generic versionsMédecins Sans Frontières Access Campaign
Sharing trade secrets is key to the pandemic agreements
Addressing this IP issue is crucial to ensuring pharmaceutical products are available in future emergenciesEllen 't Hoen (Financial Times)